Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Response Biomed Corp RPBIF

Healthcare Diagnostics & Research
"Response Biomedical Corp is engaged in the research, development, commercialization and distribution of diagnostic technologies for the medical central-lab testing, point of care (POC) testing and on-site environmental testing markets."


GREY:RPBIF - Post by User

Response Biomed Corp
Bullboard Posts
User Avatar Image
(2)
•••
Post by dimar66on Oct 30, 2008 3:34pm
248 Views
Post# 15556540

new tests

new testsI think what the press release has to say here is significant.  It says that the company is not lining itself up to become a take over of one of its current partners.  This bodes well for the longer term, this last finacing has been a bad deal for the current shareholders and I believe the Fab 5 got away with something here, but it will allow the company to move ahead to become a succesful enterprize.

"The Company is also meetingwith other potential partners to discuss the opportunity for furthermenu breadth expansion beyond infectious diseases and cardiac."

~~ dmar
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities